Semma prepares to deliver

After scaling up its beta cell generation protocol and developing a cell delivery technology, Semma Therapeutics Inc. has raised a $114 million series B round that will enable the company to bring its Type I diabetes cell therapy through clinical proof of concept.

Eight Roads Ventures and Cowen Healthcare Investments led the B round, which closed on Nov. 30. Fellow new investors ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital also participated alongside existing investors MPM Capital, F-Prime Capital Partners, Arch Venture Partners, Novartis AG (NYSE:NVS; SIX:NOVN), Medtronic plc (NYSE:MDT) and the JDRF T1D Fund. ...